Raymond James & Associates Grows Holdings in Rockwell Medical, Inc. (NASDAQ:RMTI)

Raymond James & Associates boosted its holdings in Rockwell Medical, Inc. (NASDAQ:RMTI) by 15.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 220,979 shares of the company’s stock after purchasing an additional 30,309 shares during the quarter. Raymond James & Associates owned about 0.78% of Rockwell Medical worth $418,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Great Valley Advisor Group Inc. purchased a new stake in Rockwell Medical in the 3rd quarter valued at $37,000. WealthTrust Axiom LLC purchased a new stake in Rockwell Medical in the 3rd quarter valued at $44,000. ClariVest Asset Management LLC purchased a new stake in Rockwell Medical in the 3rd quarter valued at $279,000. Finally, Armistice Capital LLC raised its position in Rockwell Medical by 631.7% in the 3rd quarter. Armistice Capital LLC now owns 2,817,000 shares of the company’s stock valued at $5,859,000 after purchasing an additional 2,432,000 shares during the last quarter. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Rockwell Medical Stock Down 3.6 %

Shares of Rockwell Medical stock opened at $1.46 on Friday. The company has a market cap of $42.72 million, a P/E ratio of -3.64 and a beta of 1.17. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.38 and a current ratio of 1.73. Rockwell Medical, Inc. has a one year low of $1.16 and a one year high of $6.24. The firm has a fifty day moving average of $1.51 and a two-hundred day moving average of $1.63.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Thursday, March 21st. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.10. The company had revenue of $22.09 million during the quarter, compared to the consensus estimate of $22.09 million. Rockwell Medical had a negative net margin of 10.09% and a negative return on equity of 39.17%. On average, analysts forecast that Rockwell Medical, Inc. will post -0.11 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright cut their price objective on shares of Rockwell Medical from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, March 25th.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.